Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview

    • 1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    • 1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
      • 1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Comparison by Type (2021-2026)
      • 1.2.2 Preface
      • 1.2.3 Eluxadoline
      • 1.2.4 Alosetron
      • 1.2.5 Rifaximin
      • 1.2.6 Loperamide
      • 1.2.7 Diphenoxylate + Atropine
      • 1.2.8 Dicyclomine and Hyoscyamine
    • 1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
      • 1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Comparison by Application: 2020 VS 2026
      • 1.3.2 Hospitals
      • 1.3.3 Clinics
      • 1.3.4 Others
    • 1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
      • 1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2015-2026
      • 1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2015-2026
      • 1.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2020 Versus 2026

    2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competition by Manufacturers

    • 2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2015-2020)
    • 2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
    • 2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2015-2020)
    • 2.4 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Sites, Area Served, Product Type
    • 2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
      • 2.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
      • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
      • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
    • 2.7 Primary Interviews with Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players (Opinion Leaders)

    3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario by Region

    • 3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
    • 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
    • 3.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
      • 3.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.3.3 U.S.
      • 3.3.4 Canada
    • 3.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
      • 3.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
      • 3.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
      • 3.5.12 Philippines
      • 3.5.13 Vietnam
    • 3.6 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
      • 3.6.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.6.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.6.3 Mexico
      • 3.6.3 Brazil
      • 3.6.3 Argentina
    • 3.7 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.7.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 U.A.E

    4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Type

    • 4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
    • 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2015-2020)
    • 4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Market Share by Type (2015-2020)
    • 4.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

    5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Application

    • 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
    • 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2015-2020)
    • 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)

    6 Company Profiles and Key Figures in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business

    • 6.1 Astellas Pharmaceuticals
      • 6.1.1 Corporation Information
      • 6.1.2 Astellas Pharmaceuticals Description, Business Overview and Total Revenue
      • 6.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
      • 6.1.4 Astellas Pharmaceuticals Products Offered
      • 6.1.5 Astellas Pharmaceuticals Recent Development
    • 6.2 Actavis
      • 6.2.1 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
      • 6.2.2 Actavis Description, Business Overview and Total Revenue
      • 6.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
      • 6.2.4 Actavis Products Offered
      • 6.2.5 Actavis Recent Development
    • 6.3 Pfizer
      • 6.3.1 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
      • 6.3.2 Pfizer Description, Business Overview and Total Revenue
      • 6.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
      • 6.3.4 Pfizer Products Offered
      • 6.3.5 Pfizer Recent Development
    • 6.4 GlaxoSmithKline
      • 6.4.1 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
      • 6.4.2 GlaxoSmithKline Description, Business Overview and Total Revenue
      • 6.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
      • 6.4.4 GlaxoSmithKline Products Offered
      • 6.4.5 GlaxoSmithKline Recent Development
    • 6.5 Salix Pharmaceuticals Ltd
      • 6.5.1 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
      • 6.5.2 Salix Pharmaceuticals Ltd Description, Business Overview and Total Revenue
      • 6.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
      • 6.5.4 Salix Pharmaceuticals Ltd Products Offered
      • 6.5.5 Salix Pharmaceuticals Ltd Recent Development
    • 6.6 AstraZenenca
      • 6.6.1 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
      • 6.6.2 AstraZenenca Description, Business Overview and Total Revenue
      • 6.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
      • 6.6.4 AstraZenenca Products Offered
      • 6.6.5 AstraZenenca Recent Development

    7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis

    • 7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Raw Materials Price Trend
      • 7.1.3 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    • 7.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
    • 8.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers

    9 Market Dynamics

    • 9.1 Market Trends
    • 9.2 Opportunities and Drivers
    • 9.3 Challenges
    • 9.4 Porter's Five Forces Analysis

    10 Global Market Forecast

    • 10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021-2026)
      • 10.1.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021-2026)
    • 10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2021-2026)
      • 10.2.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2021-2026)
    • 10.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2021-2026)
      • 10.3.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2021-2026)
    • 10.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
    • 10.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
    • 10.6 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
    • 10.7 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
    • 10.8 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.
      This report focuses on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
      Market Segment Analysis
      The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
      Segment by Type, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
      Preface
      Eluxadoline
      Alosetron
      Rifaximin
      Loperamide
      Diphenoxylate + Atropine
      Dicyclomine and Hyoscyamine

      Segment by Application
      Hospitals
      Clinics
      Others

      Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Regional Analysis
      The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
      The key regions covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report are:
      North America
      U.S.
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      Taiwan
      Indonesia
      Thailand
      Malaysia
      Philippines
      Vietnam
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      U.A.E
      Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Competitive Analysis
      This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
      The major players in global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market include:
      Astellas Pharmaceuticals
      Actavis
      Pfizer
      GlaxoSmithKline
      Salix Pharmaceuticals Ltd
      AstraZenenca

      Buy now